-
Company Insights
NewDecoding Microsoft’s YouTube Advertising Strategy in Q1 2024
The report on Microsoft's advertising strategies on YouTube during the first quarter of 2024, focuses on key products such as Microsoft Copilot and its integration with post meeting recaps and PowerPoint presentations, followed by collaboration between Microsoft Azure Quantum and PNNL. It analyzes the core themes, messaging strategies, and product benefits portrayed in these advertisements, highlighting elements such as AI Integration, Time Management, Personalization and Collaboration. Moreover, the report examines the overarching themes of Innovation, Efficiency, Sustainability and Empowerment infused...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dinutuximab Beta in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dinutuximab Beta in Neuroblastoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dinutuximab Beta in Neuroblastoma Drug Details: Dinutuximab beta (APN-311, Isqette, Qarziba)...
-
Sector Analysis
NewPeru Insurance Industry – Key Trends and Opportunities to 2028
Peru Insurance Market Report Overview The gross written premium of the Peru insurance market was PEN18.9 billion ($4.8 billion) in 2022. The market is expected to achieve a CAGR of more than 6% during 2023-2027. The following are some of the key highlights of the Peru insurance market: Life insurance was the leading revenue-generating Peruvian insurance segment in 2022. In 2022, pension was the leading line of business in the Peruvian life insurance market. Rimac Seguros y Reaseguros was the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MS-553 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MS-553 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MS-553 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MS-553 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MS-553 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MS-553 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lixisenatide in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lixisenatide in Parkinson's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lixisenatide in Parkinson's Disease Drug Details: Lixisenatide (Lyxumia, Adlyxin) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sotagliflozin in Hypertrophic Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sotagliflozin in Hypertrophic Cardiomyopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sotagliflozin in Hypertrophic Cardiomyopathy Drug Details: Sotagliflozin (Zynquista, Inpefa) is a...
-
Sector Analysis
NewNicaragua Insurance Industry – Key Trends and Opportunities to 2028
Nicaragua Insurance Market Report Overview The gross written premium of the Nicaragua insurance market was NIO9.5 billion ($261.1 million) in 2023. The market will achieve a CAGR of more than 9% during 2024-2028. The Nicaragua insurance market research report provides in-depth market analysis, information, and insights into the Nicaragua insurance industry. It provides a detailed outlook by product category as well as values for key performance indicators such as gross written premium, penetration, premium accepted and ceded, profitability ratios, and...
-
Sector Analysis
NewUnited Kingdom (UK) General Insurance Market Size and Trends by Line of Business, Distribution, Competitive Landscape and Forecast to 2028
United Kingdom (UK) General Insurance Market Report Overview The gross written premium of the United Kingdom (UK) general insurance market was GBP122.1 billion ($150.8 billion) in 2023 and will achieve a CAGR of more than 5% during 2024-2028. The UK general insurance market research report provides in-depth market analysis, including insights into the lines of business in the country’s general insurance industry. Furthermore, the report provides a detailed outlook by product category as well as values for key performance indicators,...
-
Sector Analysis
NewCosta Rica Insurance Industry – Key Trends and Opportunities to 2028
Costa Rica Insurance Market Report Overview The gross written premium of the Costa Rica insurance market was estimated to be CRC1.1 trillion ($1.6 billion) in 2023. The market will achieve a CAGR of more than 5% during 2024-2028. The Costa Rica insurance market research report provides in-depth market analysis, information, and insights into the Costa Rica insurance industry. It provides a detailed outlook by product category as well as values for key performance indicators such as gross written premium, penetration,...